Project Updates
Noumed Pharmaceutical
Credit: Jones Lang LaSalle IP
Location: Adelaide, South Australia
Project type: Pharmaceuticals manufacturing facility
Initial investment: A$100m
Expected opening: 2026
Noumed Pharmaceuticals, the Australian subsidiary of UK-based pharmaceutical company Noumed Life Sciences, is designed to produce a range of over-the-counter (OTC) pharmaceuticals for the local market.
Lek Pharmaceuticals
Credit: Lek d.d (Sandoz)
Location: Lendava, Slovenia
Project type: Biosimilar production facility
Estimated investment: $400m
Expected completion: End of 2026
The new facility of Lek Pharmaceuticals, a subsidiary of Sandoz Pharmaceuticals, will generate energy products for existing production and support a future centre for producing drug substances for biosimilars.
AbbVie
Credit: Abbvie
Location: Ludwigshafen, Germany
Project type: Research and development facility
Estimated investment: €150m
Expected completion: 2027
US-based pharmaceutical company Abbvie’s new facility will advance the development of novel therapies for chronic ailments such as cancer, Alzheimer’s, and autoimmune diseases.
